Skin Cancer

Memory killer cells have been shown to respond to immunotherapy, which is normally administered as a complement to other cancer treatments.

Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.

With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.

Pharmacists can empower their community with essential knowledge for summer skin protection to protect against skin cancer.

Investigators from the Barts Cancer Institute discovered that AMP-activated protein kinase is an essential sensor for tumor dissemination.

The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.

Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.

Pediatric drug development, which has a complex background and history, has fundamental catches based around how children are defined in the context of clinical studies.

In the initial cohort, 63% of patients with advanced melanoma achieved an objective response rate, including 6 who had a complete response and 19 who had a partial response to the combination of fianlimab and cemiplimab.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The panel corresponds to proteins that are abundant in treatment-resistant melanoma cells and may predict resistance to targeted treatment.

Study of cell exhaustion in immunotherapy-resistant tumors could significantly improve the benefits of cancer immunotherapy for patients with treatment resistant types of cancer.

Findings may offer insight into new strategies to tackle skin cancer in patients already treated with a prior line of therapy.

The treatment from Keytruda and Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

Muneeb Shah, DO, dermatologist and partner at PC Dermatology PLLC, and Reid Maclellan, MD, founder of Cortina Health Inc, tackle misinformation and myths surrounding sun screen, skin cancer, and acne.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Nivolumab met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 58% versus placebo in patients with completely resected stage 2B or 2C melanoma.

High-risk areas for disease progression include genitalia and the scalp.

Each therapy presents a different but effective treatment option.